An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer
This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.
Breast Cancer
DRUG: Capecitabine
Percent of Participants With Capecitabine as a First Line, Second Line, or Third Line Therapy, To document use of Capecitabine regimen in the management of participants with metastatic breast cancer, the choice of Capecitabine monotherapy versus combination therapy was summarized according to whether the selection was for the participant's first, second, or third line of treatment., Up to approximately 4 years|Percentage of Participants Receiving Concomitant Medications During the Study, Percentage of participants receiving concomitant medications during the study along with their prescribed monotherapy or combination therapy were reported., Up to approximately 4 years
Percentage of Participants With Relevant Medical History Assessed at Baseline, To document the metastatic breast cancer participant profile, the percentage of participants with relevant medical history as assessed at baseline was summarized., Day 1|Percentage of Participants by Histopathology Grade Diagnosis Assessed at Baseline, To document the metastatic breast cancer participant profile, the percentage of participants with histopathology grade diagnosis of moderately differentiated, well differentiated, poorly differentiated/undifferentiated as assessed at baseline was summarized., Day 1|Mean Survival Time, Up to approximately 4 years|Percentage of Participants With Adverse Events, Up to approximately 4 years
This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.